Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 120

1.

Simultaneous population pharmacokinetic modelling of atazanavir and ritonavir in HIV-infected adults and assessment of different dose reduction strategies.

Schipani A, Dickinson L, Boffito M, Austin R, Owen A, Back D, Khoo S, Davies G.

J Acquir Immune Defic Syndr. 2013 Jan 1;62(1):60-6. doi: 10.1097/QAI.0b013e3182737231.

2.

Population pharmacokinetics of atazanavir/ritonavir in HIV-1-infected children and adolescents.

Foissac F, Blanche S, Dollfus C, Hirt D, Firtion G, Laurent C, Treluyer JM, Urien S.

Br J Clin Pharmacol. 2011 Dec;72(6):940-7. doi: 10.1111/j.1365-2125.2011.04035.x.

3.

Beneficial pharmacokinetic interaction between atazanavir and lopinavir/ritonavir.

Pham PA, Flexner C, Parsons T, Vasist L, Fuchs E, Carson K, Agarwala S, Barditch-Crovo P.

J Acquir Immune Defic Syndr. 2007 Jun 1;45(2):201-5.

PMID:
17414932
4.

Model-based approach for optimization of atazanavir dose recommendations for HIV-infected pediatric patients.

Hong Y, Kowalski KG, Zhang J, Zhu L, Horga M, Bertz R, Pfister M, Roy A.

Antimicrob Agents Chemother. 2011 Dec;55(12):5746-52. doi: 10.1128/AAC.00554-11. Epub 2011 Sep 19.

5.

Population pharmacokinetics and dose optimisation of ritonavir-boosted atazanavir in Thai HIV-infected patients.

Punyawudho B, Thammajaruk N, Ruxrungtham K, Avihingsanon A.

Int J Antimicrob Agents. 2017 Mar;49(3):327-332. doi: 10.1016/j.ijantimicag.2016.11.019. Epub 2017 Jan 18.

PMID:
28109702
6.

Pharmacokinetics of atazanavir/ritonavir among HIV-infected Thai children concomitantly taking tenofovir disoproxil fumarate.

Bunupuradah T, Techasaensiri C, Keadpudsa S, Thammajaruk N, Srimuan A, Sahakijpicharn T, Prasitsuebsai W, Ananworanich J, Puthanakit T; HIV-NAT 146 Study Team.

Pediatr Infect Dis J. 2014 Dec;33(12):e316-9. doi: 10.1097/INF.0000000000000469.

PMID:
24983717
7.

Population pharmacokinetics of ritonavir-boosted atazanavir in HIV-infected patients and healthy volunteers.

Dickinson L, Boffito M, Back D, Waters L, Else L, Davies G, Khoo S, Pozniak A, Aarons L.

J Antimicrob Chemother. 2009 Jun;63(6):1233-43. doi: 10.1093/jac/dkp102. Epub 2009 Mar 28.

8.

Pharmacokinetics of saquinavir, atazanavir, and ritonavir in a twice-daily boosted double-protease inhibitor regimen.

von Hentig N, Müller A, Rottmann C, Wolf T, Lutz T, Klauke S, Kurowski M, Oertel B, Dauer B, Harder S, Staszewski S.

Antimicrob Agents Chemother. 2007 Apr;51(4):1431-9. Epub 2007 Feb 12.

9.

Population pharmacokinetics of lopinavir/ritonavir (Kaletra) in HIV-infected patients.

López Aspiroz E, Santos Buelga D, Cabrera Figueroa S, López Galera RM, Ribera Pascuet E, Domínguez-Gil Hurlé A, García Sánchez MJ.

Ther Drug Monit. 2011 Oct;33(5):573-82. doi: 10.1097/FTD.0b013e31822d578b.

PMID:
21912331
10.

Population pharmacokinetics of atazanavir in patients with human immunodeficiency virus infection.

Colombo S, Buclin T, Cavassini M, Décosterd LA, Telenti A, Biollaz J, Csajka C.

Antimicrob Agents Chemother. 2006 Nov;50(11):3801-8. Epub 2006 Aug 28.

11.

The effect of atazanavir/ritonavir on the pharmacokinetics of an oral contraceptive containing ethinyl estradiol and norgestimate in healthy women.

Zhang J, Chung E, Yones C, Persson A, Mahnke L, Eley T, Xu X, Bertz R.

Antivir Ther. 2011;16(2):157-64. doi: 10.3851/IMP1724.

PMID:
21447864
12.

Pharmacokinetics of two common antiretroviral regimens in older HIV-infected patients: a pilot study.

Dumond JB, Adams JL, Prince HM, Kendrick RL, Wang R, Jennings SH, Malone S, White N, Sykes C, Corbett AH, Patterson KB, Forrest A, Kashuba AD.

HIV Med. 2013 Aug;14(7):401-9. doi: 10.1111/hiv.12017. Epub 2013 Feb 24.

13.

Monitoring atazanavir concentrations with boosted or unboosted regimens in HIV-infected patients in routine clinical practice.

Moltó J, Santos JR, Valle M, Miranda C, Miranda J, Blanco A, Negredo E, Clotet B.

Ther Drug Monit. 2007 Oct;29(5):648-51.

PMID:
17898658
14.

Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures.

Johnson M, Grinsztejn B, Rodriguez C, Coco J, DeJesus E, Lazzarin A, Lichtenstein K, Rightmire A, Sankoh S, Wilber R.

AIDS. 2005 Apr 29;19(7):685-94.

PMID:
15821394
15.

Ritonavir-boosted atazanavir-lopinavir combination: a pharmacokinetic interaction study of total, unbound plasma and cellular exposures.

Colombo S, Buclin T, Franc C, Guignard N, Khonkarly M, Tarr PE, Rochat B, Biollaz J, Telenti A, Decosterd LA, Cavassini M.

Antivir Ther. 2006;11(1):53-62.

PMID:
16518960
16.

Effect of rifampin on steady-state pharmacokinetics of atazanavir with ritonavir in healthy volunteers.

Burger DM, Agarwala S, Child M, Been-Tiktak A, Wang Y, Bertz R.

Antimicrob Agents Chemother. 2006 Oct;50(10):3336-42.

17.

Safety and exposure of once-daily ritonavir-boosted atazanavir in HIV-infected pregnant women.

Conradie F, Zorrilla C, Josipovic D, Botes M, Osiyemi O, Vandeloise E, Eley T, Child M, Bertz R, Hu W, Wirtz V, McGrath D.

HIV Med. 2011 Oct;12(9):570-9. doi: 10.1111/j.1468-1293.2011.00927.x. Epub 2011 May 16.

18.

Pharmacokinetic interactions of CEP-1347 and atazanavir in HIV-infected patients.

Ma Q, Gelbard HA, Maggirwar SB, Dewhurst S, Gendelman HE, Peterson DR, DiFrancesco R, Hochreiter JS, Morse GD, Schifitto G.

J Neurovirol. 2013 Jun;19(3):254-60. doi: 10.1007/s13365-013-0172-z. Epub 2013 Jun 5.

19.

A low dose of ritonavir-boosted atazanavir provides adequate pharmacokinetic parameters in HIV-1-infected Thai adults.

Avihingsanon A, van der Lugt J, Kerr SJ, Gorowara M, Chanmano S, Ohata P, Lange J, Cooper DA, Phanuphak P, Burger DM, Ruxrungtham K.

Clin Pharmacol Ther. 2009 Apr;85(4):402-8. doi: 10.1038/clpt.2008.244. Epub 2008 Dec 31.

PMID:
19118378
20.

Population pharmacokinetic modelling of the changes in atazanavir plasma clearance caused by ritonavir plasma concentrations in HIV-1 infected patients.

Moltó J, Estévez JA, Miranda C, Cedeño S, Clotet B, Valle M.

Br J Clin Pharmacol. 2016 Dec;82(6):1528-1538. doi: 10.1111/bcp.13072. Epub 2016 Sep 13.

PMID:
27447851

Supplemental Content

Support Center